Guillain-Barré syndrome (GBS) is referred to a rare condition in which a person’s self-immune system attacks his own peripheral nerves. The disease was first detected by the French physician Jean-Baptiste Octave Landry in 1859. After this during 1916, Georges Guillain, Jean Alexandre Barré, and André Strohl also confirmed the disease onset in some soldiers. The disease can affect the people of all ages but more common in adult males. The disease has recovery, if treated. In case of severity which is rare can lead to total paralysis. Guillain-Barré syndromecan adversely affect the nerves that control muscle movement, transmit pain, temperature, feeling the touch sensations. Muscle weaknesses, loss of sensation in the legs and/or arms are the resultant symptoms may arise in the patient suffering from GBS. The symptoms will start in the legs and further spread to face and arms. In GBS 20–30% peoples may experience the chest muscle affected and difficulty in breathing. Sometimes the swallow and speak abilities also get affected. Most of peoples recover fully from GBS, but some people have long-term nerve damage. 3–5% of GBS patients may die from complications, which include paralysis of the muscles that control breathing, blood infection, lung clots or cardiac arrest. As per the National Health Portal web site information the cause of GBS is unknown. It sometimes linked with triggering by an infectious illness like gastrointestinal infection or a lung infection. Some countries from Europe and Asia have also reported familial occurrence of GBS. According to World Health Organization (WHO) overall incidence of GBS is 0.4 to 4.0 people per 100000 per year.1

Keywords: Autoimmune disease; Guillain-Barré syndrome (GBS); Systemic lupus erythematous; World health organization (WHO).